Galectin Therapeutics
GALT
62 hedge funds and large institutions have $13M invested in Galectin Therapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 8 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% less funds holding
Funds holding: 63 → 62 (-1)
40% less capital invested
Capital invested by funds: $21.5M → $13M (-$8.5M)
98% less call options, than puts
Call options by funds: $15K | Put options by funds: $679K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$332K |
| 2 |
Morgan Stanley
New York
|
+$328K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$309K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$176K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$3.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$612K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$186K |
| 4 |
BCA
Benchmark Capital Advisors
New York
|
-$148K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$141K |
GALT Hedge Fund Activity: Q4 2014 in Review
62 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2014, worth a combined $13M — down 40% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GALT positions and 8 closed out — a net gain of 1 holder — while 22 added to existing stakes and 16 trimmed.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $332K. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $3.4M sold.
- 62 institutional investors held Galectin Therapeutics (GALT) as of Q4 2014, down from 63 in Q3 2014.
- Funds reported $13M of Galectin Therapeutics stock for Q4 2014, down 40% quarter-over-quarter.
- 9 funds opened new Galectin Therapeutics positions in Q4 2014 and 8 closed out, a net change of +1 holder.
- The largest Galectin Therapeutics buyer in Q4 2014 was D.E. Shaw & Co, an estimated $332K added.
- The largest Galectin Therapeutics seller in Q4 2014 was Catalyst Capital Advisors, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2014.